April 18, 2016
(STAT News) – Now that Theranos faces the prospect of a crippling ban on its operations by federal officials, let’s get past its implosion and talk about the real implications for the rest of the diagnostic sector. Diagnostic technology, which is often at the center of medical care, has traditionally received little attention from investors. The Theranos debacle threatens to make investors even less likely to support diagnostic companies in the future, slowing innovation and delaying the introduction of life-saving tests.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.